Strengthening Pathways For Cell And Gene Therapies

Cell and gene therapies offer transformative benefits to patients facing limited treatment options, supported by record funding, clinical research, and new launches. However, challenges within the health system infrastructure and the complexities of patient journeys remain significant barriers to their future success and sustainability. Uncertainty surrounds the sector's trajectory, underscoring the need for a comprehensive understanding of its current state and potential evolution in the years ahead.

This report examines a diverse range of therapies, including cell-based immunotherapies, cell therapies, gene therapies, and tissue-engineered products (excluding RNA therapeutics). It provides insights into the entire product lifecycle, beginning with pre-commercial activities like funding and clinical research, and addresses hurdles to commercialization such as infrastructure requirements, reimbursement, and patient access.

By evaluating eight key indicators, we outline potential future scenarios for the sector up to 2035 and beyond. We aim to stimulate informed discussions on the sector's future and the role of cell and gene therapies in shaping healthcare. Produced independently by the IQVIA Institute for Human Data Science, this report is a public service initiative, free from industry or government funding, with contributions from numerous experts acknowledged gratefully.